Breakout Session 1 - Prior Knowledge as a Means to Further QbD ImplementationFacilitated by Ruojia Li, Bristol-Myers Squibb
Breakout Session 2 – Opportunities for Working with Big Data in BiologicalsFacilitated by JoAnn Coleman, Spark Therapeutics
Breakout Session 1 – CMC Statistics Advancement in a Regulated IndustryFacilitated by Laura Pack, Rezolute
Breakout Session 2 – Patient-Centric SpecificationsFacilitated by Tim Schofield, IABS; CMC Science LLC
Breakout Session 1- Current Trends and Issues in Continuous Manufacture Driving Drug DevelopmentFacilitated by Areti Manola, Janssen
Breakout Session 2 – Updating Limits Using Bayesian MethodsLink to Abstract
Facilitated by Tara Scherder, Synolostats, LLC
Breakout Session 1- Case Studies of Acceleration with a Lifecycle ApproachFacilitated by Katherine Giacoletti, Merck & Co., Inc.
Breakout Session 2 – Bayesian Success Stories in CMCFacilitated by Chuck Miller, Merck & Co., Inc.
Access to meeting’s slides is given to meeting’s participants for a period of 4 weeks after the meeting.
A unique Login and password are sent by email to participants right after the meeting.
Afterwards the slides are only accessible to IABS member, using their Member Login and Password.
The International Alliance for Biological Standardization (IABS) is an independent, non-profit scientific Alliance, governed by Articles 60-79 of the Swiss Civil code and by its Constitution. Its office is located in Geneva (Switzerland). IABS has members in over 50 countries.
IABS is devoted to the scientific and medical advancement of biologicals, by facilitating communication among those who develop, produce and regulate biological products for human and animal health.
Reports and proceedings of IABS conferences and workshops appear in its journal Biologicals, published by Elsevier and /or in the series Developments in Biologicals published by Karger.
As an Individual Member of IABS, you will:
For more information on how to become a member of IABS, please visit: www.iabs.org